68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

Inclusion Criteria: * Signed informed consent * Subjects of either sex, aged ≥18 years * Histologically and/or clinically confirmed and/or suspected NET and/or A diagnostic imaging study including but not limited to CT or MRI or FDG PET/CT, NaF PET/CT, bone scan, ultrasound, etc. of the tumor region or suspected area within the 4 weeks of dosing day * Recent Blood test results (within 2-4 weeks predose) as WBC: ≥2 x 109/L, Haemoglobin: ≥8.0 g/dL, Platelets: ≥50 x 109/L, ALT, AST, AP:≤ 5 times ULN \[ ULN for ALT, AST and AP is 70, 20 and 20 Units/I respectively\], Bilirubin: ≤3 times ULN \[ULN for total bilirubin is 1.3mg/dL\] * Serum creatinine: Serum creatinine: \<170 μmol/L * egative pregnancy test in women capable of child-bearing Exclusion Criteria: * Known hypersensitivity to DOTA, to 68Gallium, to Octreotate or to any of the excipients of 68Ga-DOTATATE * Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (within 28 days) and Sandostatin® (within 2 days) prior to study imaging. If a patient is on Sandostatin® LAR a wash-out phase of 28 days is required before the injection of the study drug * Pregnant or breast-feeding women * Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study